Oral administration of <scp>l</scp>-carnitine improves the clinical outcome of fertility in patients with IVF treatment

Kitano, Yuko F.; Hashimoto, Shu; Matsumoto, Hiroshi; Yamochi, Takayuki; Yamanaka, M.; Nakaoka, Yoshiharu; Fukuda, Aisaku; Inoue, Masayasu; Ikeda, Tomoaki; Morimoto, Yoshiharu

doi:10.1080/09513590.2018.1431769

Cited by 16 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we have relied on a mouse DHEA model of PCOS to demonstrate that oral administration of acyl-L-carnitines alleviates ovarian dysfunctions associated with this syndrome and to explore whether the co-administration of PLC provides better activity. In order to select the proper protocol for LC and ALC administration we based on studies on male and female fertility [10,14,30,[35][36][37][38]. For PLC, since there are no studies on fertility, we employed the minimum effective dose identified by Delaney et al [39].…”

Section: Discussionmentioning

confidence: 99%

Regulatory Functions of L-Carnitine, Acetyl, and Propionyl L-Carnitine in a PCOS Mouse Model: Focus on Antioxidant/Antiglycative Molecular Pathways in the Ovarian Microenvironment

et al. 2020

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a complex metabolic disorder associated with female infertility. Based on energy and antioxidant regulatory functions of carnitines, we investigated whether acyl-L-carnitines improve PCOS phenotype in a mouse model induced by dehydroepiandrosterone (DHEA). CD1 mice received DHEA for 20 days along with two different carnitine formulations: one containing L-carnitine (LC) and acetyl-L-carnitine (ALC), and the other one containing also propionyl-L-carnitine (PLC). We evaluated estrous cyclicity, testosterone level, ovarian follicle health, ovulation rate and oocyte quality, collagen deposition, lipid droplets, and 17ß-HSD IV (17 beta-hydroxysteroid dehydrogenase type IV) expression. Moreover, we analyzed protein expression of SIRT1, SIRT3, SOD2 (superoxide dismutase 2), mitochondrial transcriptional factor A (mtTFA), RAGE (receptor for AGEs), GLO2 (glyoxalase 2) and ovarian accumulation of MG-AGEs (advanced glycation end-products formed by methylglyoxal). Both carnitine formulations ameliorated ovarian PCOS phenotype and positively modulated antioxidant molecular pathways in the ovarian microenvironment. Addition of PLC to LC-ALC formulation mitigated intraovarian MG-AGE accumulation and increased mtTFA expression. In conclusion, our study supports the hypothesis that oral administration of acyl-L-carnitines alleviates ovarian dysfunctions associated with this syndrome and that co-administration of PLC provides better activity. Molecular mechanisms underlying these effects include anti-oxidant/glycative activity and potentiation of mitochondria.

show abstract

Section: Discussionmentioning

confidence: 99%

Regulatory Functions of L-Carnitine, Acetyl, and Propionyl L-Carnitine in a PCOS Mouse Model: Focus on Antioxidant/Antiglycative Molecular Pathways in the Ovarian Microenvironment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…33 Further, a clinical study reported that administration of Lcarnitine to patients who were previously failure to in vitro fertilization-embryo transfer, significantly improved the quality of embryo on Days 3 and 5 after insemination. 34 As coadministration with clomiphene citrate, we found that carnitine supplement could significantly improve ovulation and pregnancy rates, with weakened power due to limited studies. This is warranted to be further validated and clarified the underlying mechanism.…”

Section: Discussionmentioning

confidence: 94%

Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis

Gong

Jiang

Hui

et al. 2023

Clinical Endocrinology

View full text Add to dashboard Cite

Objectives To quantify the effect of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with Polycystic ovary syndrome (PCOS). Design A systematic review and meta‐analysis were conducted. Patients Women with PCOS diagnosed by Rotterdam or Androgen Excess Society (AES) criteria and taking carnitine supplement were assessment. Measurements Fertility outcomes (ovulation, clinical pregnancy, live birth, and miscarriage), lipid parameters (BMI, triglyceride, total cholesterol, high‐density lipoprotein, low‐density lipoprotein), fasting glucose and insulin, and Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR). Results In total, 839 participants were included in this analysis. The dosage of carnitine and treatment duration reported by studies varied from 250 mg to 3000 mg daily and 84 to 90 days, respectively. The publication bias was absent. Compared with placebo, carnitine significantly improved ovulation rates (RR 3.42, 95% CI 2.39 to 4.89, I2 = 0%) and pregnancy rates (RR 11.05, 95% CI 1.21 to 100.58, I2 = 79%). None of included studies reported live birth. After treatment, carnitine resulted in significant reductions relative to baseline in body mass index (BMI, MD −0.93 kg/m2, 95% CI −1.15 to −0.70, I2 = 55.0%), insulin levels (MD −2.47 mIU/L, 95% CI −4.49 to −0.45, I2 = 0%) and the Homeostasis Model Assessment index (MD −0.67, 95% CI −1.20 to −0.14, I2 = 0%) than placebo, but not for lipid profiles including triglyceride, total cholesterol, and low‐density lipoprotein. Conclusion With the available literature, carnitine seems to improve ovulation and clinical pregnancy and insulin resistance, BMI in women with PCOS. These effects are warranted to be further validated, due to insufficient statistical power.

show abstract

“…A recent study showed that oral administration of L-carnitine improved the developmental potential and clinical outcome of their oocytes following insemination in patients who failed to conceive. There was no abnormality in Apgar score values and birth weight (Kitano et al, 2018). Another experiment showed that oral L-Carnitine administration with metformin improved the rate of ovulation, pregnancy, and menstrual regulation among clomipheneresistant obese PCOS women (El Sharkwy et al, 2019).…”

Section: In Vivo Experimental Modelsmentioning

confidence: 94%

Biological roles of l‐carnitine in oocyte and early embryo development

Liu

Weng

et al. 2021

Molecular Reproduction Devel

View full text Add to dashboard Cite

Poor oocyte quality is responsible for female infertility. Multiple studies have been carried out to find supplements to enhance oocyte quality and mitigate infertility problems. L-carnitine and its derivatives have diverse roles in developing oocytes and early embryos. This review focuses on the in vitro and in vivo studies that using L-carnitine alone or in combination with other supplements for oocyte quality enhancement. The key roles of L-carnitine in oocyte quality and embryo growth were summarized, and the underlying mechanism was also elucidated. L-carnitine helps in the lipid metabolism process by controlling the transfer of fatty acids to mitochondria for β-oxidation. L-carnitine modulates glucose metabolism and enhances respiratory chain enzyme activity. Furthermore, it acts as an antioxidant to prevent oxidative damage and inhibit apoptosis, a signal in response to oxidative stress. Results show the potential of L-carnitine as a potential agent in assisted reproductive technology to improve oocyte quality and the subsequent embryonic development.cryopreservation, embryo development, in vitro maturation, in vivo models, L-Carnitine, oocyte quality | INTRODUCTIONOocyte developmental potential is associated with its capacity to successfully resume meiosis, be fertilized, implanted in the uterus, and finally develop into a healthy offspring (Dunning et al., 2014). Poor oocyte quality is one of the major causes of decline in female fertility. To date, enormous nutrients and pharmaceutical drugs have been proposed to enhance oocyte quality and attenuate reproductive disorders, such as different types of hormones, proteins, growth factors, and antioxidants. However, adverse effects and incidences have been reported on other systems (Rutkowski & Grzegorczyk, 2012). Considering this point, several experimental studies have been carried out in vivo or in vitro to

show abstract

Oral administration of l-carnitine improves the clinical outcome of fertility in patients with IVF treatment

Cited by 16 publications

References 34 publications

Regulatory Functions of L-Carnitine, Acetyl, and Propionyl L-Carnitine in a PCOS Mouse Model: Focus on Antioxidant/Antiglycative Molecular Pathways in the Ovarian Microenvironment

Regulatory Functions of L-Carnitine, Acetyl, and Propionyl L-Carnitine in a PCOS Mouse Model: Focus on Antioxidant/Antiglycative Molecular Pathways in the Ovarian Microenvironment

Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis

Biological roles of l‐carnitine in oocyte and early embryo development

Contact Info

Product

Resources

About